Video

Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma

Author(s):

Jeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center
Conference|ASCO Annual Meeting

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the design and results of the CheckMate-064 trial, which examined outcomes in patients who received nivolumab (Opdivo) given sequentially with ipilimumab (Yervoy) in patients with advanced melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the design and results of the CheckMate-064 trial, which examined outcomes in patients who received nivolumab (Opdivo) given sequentially with ipilimumab (Yervoy) in patients with advanced melanoma.

Related Videos
Ashkan Emadi, MD, PhD
Alexis LeVee, MD
Martin Dreyling, MD
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
John H. Strickler, MD
Junjie Li, MD
Peter Riedell, MD
Jorge Cortes, MD
Michael R. Bishop, MD
Lori A Leslie, MD
Related Content
Cervical Cancer| lertsakwiman – stock.adobe.com
January 6th 2025

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Melanoma | Maris– stock.adobe.com
January 4th 2025

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Lynn M. Schuchter, MD
January 1st 2025

A 30-Year Commitment to Advancing Melanoma Care

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies